Multiple Sclerosis Leadership Summit

Activity Details
  • Credit Amounts:
  • Cost: Free
  • Release: Sep 15, 2015
  • Expires: Aug 30, 2017
  • Average User Rating:
    ( Ratings)

Faculty

Joseph R.  Berger Joseph R. Berger, MD, FACP, FAAN, FANA
Professor of Neurology
Chief of MS Division of the
Department of Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Bruce A.  Cohen Bruce A. Cohen, MD
Northwestern Comprehensive MS Program
Northwestern University Feinberg School of Medicine
Chicago, IL

Needs Statement

The field of multiple sclerosis treatment is rapidly evolving through important advances in clinical investigation and emerging scientific discoveries. Leading experts from MS research and comprehensive care institutions participated in an MS Leadership Summit at the New York Academy of Sciences to review current treatment paradigms and to identify, discuss, and debate emerging evidence.

The continuing education program derived from the live meeting features the MS Leadership Summit proceedings in a series of scientific presentations, along with expert commentary, reinforced by biweekly clinical case challenges. Each presentation and each case study on the website is eligible for individual CME, AOA, and CNE credits. The goal is to facilitate an understanding of evidence-based best practices, emerging paradigms, and pivotal data to be incorporated into clinical practice in order to improve patient management and outcomes.

To participate in this activity, click here.

Target Audience

Neurologists and other physicians specializing in the treatment of MS patients, as well as MS Clinical Specialist Nurses and Nurse Practitioners practicing in MS comprehensive care centers, free-standing MS centers, private and group practices, MS academic and research programs, rehabilitation centers, VA MS Centers of Excellence (COE) programs, pediatric MS COE programs, and long-term care facilities.

Objectives

Advances in Treatment & Standards of Care
• Review current treatment landscape and emerging therapeutic innovations in MS;
• Describe the benefits and limitations of current therapies, formulations, and delivery mechanisms for MS;
• Discuss the impact and data supporting early treatment with disease-modifying drug therapy upon presentation of clinically isolated syndrome and the challenges associated with confirming a diagnosis of MS;
• Identify practice-related opportunities that clinicians may adapt to help improve MS treatment adherence; and
• Counsel patients on monitoring, prevention, and management strategies that can reduce injection- site and hypersensitivity reactions associated with DMTs


Comorbidity & Symptom Management Strategies
• Discuss monitoring and management strategies associated with chronic immunosuppressive therapy (infertility, secondary malignancies, opportunistic infections);
• Consider patient risk assessment to mitigate a specific drug’s toxicity profile as well as long-term complications of immunosuppression;
• Review the literature on the comorbidities and disease-related symptoms of MS and summarize the evidence for treatments that have been or may be used to alleviate them; and
• Identify various rehabilitation services that may be provided across the different stages of MS disease


Clinical Research Topics on the Horizon
• Describe treatment challenges, options, emerging strategies for patients with aggressive (i.e., rapidly progressive, inflammatory phase) MS;
• Provide guidance on personalizing therapy to optimize outcomes (supporting clinical data, MRI, and biomarker correlates);
• Assess new clinical data/strategies using stem cells and other neuroprotective and neuroregenerative agents to overcome remyelination failure in MS; and
• Review new stage-dependent measures that can reliably detect small changes in disability and reliably reflect long-term changes in sustained disease progression in a complex population.

Faculty Disclosure

Peter Calabresi, MD has disclosed that he has received grants and research support from Biogen IDEC, Novartis and MedImmune.

Bruce A. Cohen, MD has disclosed that he is consultant for Acorda, EMD Serono, Genentech, Genzyme/Sanofi Aventis, Novartis and TEVA Neurosciences.  He has received grants and research support from Biogen-IDEC, Genentech/Hoffman La Roche and Novartis.

Ellen Mowry, MD, MCR has disclosed that she has received grants and research support from TEVA Neuroscience and Biogen IDEC.

Joseph R. Berger, MD has disclosed that he is consultant for Amgen, Astra-Zeneca, Bristol-Meyers-Squibb, Eisai, Janssen, Millenium, Parexel, Pfizer, Roche, Takeda, Genentech, Novartis, Incyte, Inhibikase, Johnson & Johnson and TEVA.  He has received grants and research support from Biogen and PML Consortium.

Patricia K. Coyle, MD, FAAN, FANA has disclosed that she is consultant for AbbVie, Accordant, Acorda, Bayer, Biogen, Genentech/Roche, Genzyme/Sanofi, Novartis, Serono and TEVA.  She has received grants and research support from Actelion, Novartis and Opexa.

Michael O'Dell, MD has disclosed that he is consultant for Ipsen, Bioness and Ottobach.  He has received grants and research support from Ipsen and SmartPatch.

Carrie Lyn Sammarco, DNP, FNP-C, MSCN has disclosed that she has received an honoraria from Biopen IDEC, EMD Serono, Novartis, Pfizer and TEVA Questcor.

Acknowledgement

This activity is jointly provided by the University of North Texas Health Science Center and Letters & Sciences.

The activity was supported by PACE - General.